does it matter? he’s doing it. imo that’s all that matters.
2 Likes
I wonder if this will change a few vaccine-reluctant folks’ minds:
https://www.reddit.com/r/science/comments/naok95/covid19_found_in_penile_tissue_could_contribute/
There is a link to a scientific paper in the OP, but it appears to be down due to Reddit-induced volume. An author of the paper responded in the comments. NSFW due to the anatomy involved and, well, it’s Reddit.
1 Like
You’re right, it doesn’t. I just had a thought.
Anatomy isn’t NSFW where i work. Our claims files routinely name body parts, and those body parts are sometimes injured.
1 Like
When you got 'em by the short and curlies, their hearts and minds will follow.
1 Like
When my company first installed a net-nanny on connections to/from the outside, I remember a bunch of ocean marine claims folks getting very upset very quickly. Apparently male genitalia are frequently injured in Jones Act claims.
(And then there was the time when HR found out the hard way exactly what the Entertainment unit’s underwriters meant when they said they were getting into a “clubs” segment.)
I tend to apply NSFW warnings when certain bits and pieces of anatomy are mentioned because some folks are uptight about such things. Better to mention and let people use judgment based on their own situation, than to give an unobservant person an unwanted surprise.
1 Like
My stepdaughter (age 19) is a pharmacy tech and she’s been trained to give it.
Not a big deal. Giving shots is easy. I was 10 when my brother was diagnosed with type 1 diabetes and I learned how to give him injections. 
It’s intramuscular, which is slightly harder than subcutaneous, but yeah. I think most adults with normal dexterity and intelligence could learn to do it in a couple of hours. That includes learning how to do the paperwork, talking to the patient about allergies, etc.
3 Likes
I had a similar thought process yesterday when I was waiting for #2 yesterday. Two couples in their 60s (one of the men was wearing a Navy vet hat) did a walk-in and were filling out the info needed before the shot. That group has been eligible for a few months, so I was thinking that they were in the hesitant crowd that finally decided get a shot.
2 Likes
Wow, went to make an appt for my son last night (13yo, so Pfizer), and Walgreen’s basically had open slots every 15 minutes from 8:30AM-5:15PM. So he’ll get one today and one June 3, and we should all feel reasonably safe about heading to Maui July 1.
5 Likes
just scheduled for my other two kids for Sunday morning. Woot!
Lots of slots open.
7 Likes
many or most of the places here, you don’t actually need an appointment anymore.
1 Like
Yeah I feel sorry for all the old people who struggled to find an appointment and couldn’t choose which vaccine they got.
most of the older people got moderna or pfizer. are they all that different from each other where a choice is that important?
I didn’t want Moderna because it’s an extra week between #1 and #2. I’ve already had it with waiting, so I didn’t want to wait the extra week. If I had known they’d unpause J&J so quickly, I would have just waited and got that, and I’d be “fully protected” by now.
most of the older people got it months ago though. if they didn’t get it months ago, they get to choose now.
Yeah I just remember seeing a lot of FB posts back in February about how difficult it was to find an appointment. I had one friend freak out because the only appointment for shot#2 was outside the recommended window.
oh yeah, it was. my father’s nurse has some mad phone skills and got my parents an appointment immediately, but others weren’t as lucky, but most of them did get appointments before it opened up to the rest of us. it got easy after a while.
Difference between J&J and Pfizer is only one week since it takes 4 weeks to be fully protected with J&J and 5 weeks with Pfizer if you schedule the appointments precisely 3 weeks apart.
Looks like you may not be able to choose J&J much longer.
Johnson & Johnson vaccine shipments to states dwindle to zero as production freeze continues
Allocations dry up after contamination crisis at Baltimore subcontractor Emergent BioSolutions
The Biden administration will stop shipping doses of Johnson & Johnson coronavirus vaccine to states next week, according to the Centers for Disease Control and Prevention, as a contamination incident two months ago at a Baltimore subcontractor continues to disrupt domestic production.
No new shipments for the one-shot Johnson & Johnson vaccine were included Thursday in the CDC’s weekly update on expected vaccine shipments. Shipments of the first and second doses of the two-shot Pfizer-BioNTech and Moderna vaccines will continue next week uninterrupted, according to the CDC shipment schedules.
The last federal allocation of Johnson & Johnson vaccine for states was for this week. That was a paltry 600,000 doses. Weekly allocations have been running at more than 10 million for Pfizer shots and nearly 8 million for Moderna.
The lack of new shipments of Johnson & Johnson’s vaccine may not have an immediate impact on individual states, which have some stockpiles, Marcus Plescia, chief medical officer for the Association of State and Territorial Health Officials, said Thursday. But it could cause concern if the shortage continues, he said.
The convenience of Johnson & Johnson’s single-shot vaccine, and the relative ease of storage and handling compared with the Pfizer and Moderna vaccines, has continued to bolster demand in many states, Plescia said.
“Everybody’s just hoping that this is just a little period that we’re going through and things will get back to where they were previously,” he said.
Some of the local reserves are left over from a 10-day pause in Johnson & Johnson vaccinations that the Biden administration called in April while it evaluated rare but dangerous blood clots associated with the vaccine. That pause was lifted April 23.
The Johnson & Johnson vaccine received an emergency-use authorization from the Food and Drug Administration in February. The company began delivering millions of shots in March, with a peak allocation to states of 5 million doses for the week beginning April 5.
All of its doses have been imported from a Johnson & Johnson manufacturing facility in the Netherlands. Emergent BioSolutions, a U.S. biodefense contractor that is manufacturing Johnson & Johnson’s vaccine in the United States, has been struck by problems and has not received FDA certification for domestic production.
Last month, the Biden administration stopped Johnson & Johnson vaccine production at Emergent and removed a production line for a coronavirus vaccine made by AstraZeneca after a cross-contamination crisis ruined 15 million Johnson & Johnson doses. The FDA issued a harsh inspection report that found unsanitary conditions and a lack of training and procedures to prevent contamination of vaccine batches. None of the contaminated vaccine made it into Johnson & Johnson’s supply chain.
Emergent said this week that it is working with the FDA and Johnson & Johnson to fix the problems, win certification and get production back on line.
“We have already started making improvements and we are fully committed to making the necessary short- and long-term enhancements to meet or exceed FDA’s standards,” the company said Tuesday. Johnson & Johnson, which has taken over production oversight at the Emergent plant, provided no details but said it is continuing to “partner closely” with the U.S. government on the facility.
Emergent officials are scheduled to appear at a hearing of the House select subcommittee on the coronavirus crisis on Wednesday.
Biden administration officials informed governors on a Tuesday call that no new Johnson & Johnson doses will be allocated next week, according to two people who participated and spoke on the condition of anonymity because the conversation was private.
During the previous week’s call, Jeff Zients, coordinator of the White House’s coronavirus task force, said more doses will be available once federal regulators clear use of Emergent’s Baltimore plant, according to a recording of the conversation obtained by The Washington Post.
While stressing that approval is up to the Food and Drug Administration, Zients said, “Everything we’re hearing is that it’s a matter of a week or two, and then there’s going to be a significant amount, because once it’s cleared, my understanding is that there’s a lot ready to go.”
Demand for the single-shot vaccine varies widely by state.
Even as officials in South Carolina planned to cut back orders of the Pfizer and Moderna vaccines, they said they would continue to claim as much of the Johnson & Johnson vaccine as is made available to them because it is easier to store.
“The reason we’re taking all of our [Johnson & Johnson vaccine] is because we’ve got different plans for the [Johnson & Johnson] vaccine, from mobile clinics,” Jane Kelly, assistant state epidemiologist, said last week. “It can sit for six months in the fridge, so it’s easy to store it.”
Connecticut, meanwhile, has stopped ordering the Johnson & Johnson vaccine because the state has not been able to use up a stockpile of that product, said Josh Geballe, the state’s chief operating officer. When use of the vaccine was paused nationwide last month, Connecticut had about 125,000 doses on hand, he said.
Since the pause was lifted, the state has been able to administer only about 6,000 doses. “We have seen some demand for J&J, but well below the levels we had seen before the pause,” Geballe said.